Measurable residual disease recurrence as early warning of relapse in acute myeloid leukemia

To investigate the clinical features and outcomes of measurable residual disease recurrence (MRD-R) by multiparameter flow cytometric in acute myeloid leukemia (AML). We retrospectively analyzed clinical characteristic, residual disease status and outcomes of 767 newly diagnosed AML patients achiev...

Full description

Saved in:
Bibliographic Details
Main Authors: Benfa Gong, Miao Yang, Shaowei Qiu, Bingcheng Liu, Ying Wang, Yingchang Mi, Hui Wei, Jianxiang Wang
Format: Article
Language:English
Published: Ferrata Storti Foundation 2025-06-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/12103
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the clinical features and outcomes of measurable residual disease recurrence (MRD-R) by multiparameter flow cytometric in acute myeloid leukemia (AML). We retrospectively analyzed clinical characteristic, residual disease status and outcomes of 767 newly diagnosed AML patients achieving complete remission within two cycles of induction at our center. Totally, 171 (22.3%) patients experienced MRD-R during follow-up. Patients with MRD-R had inferior outcomes compared to those without MRD-R, with 3-year cumulative incidence of morphologic relapse (CIR), relapse-free survival (RFS) and overall survival (OS) at 63.6% vs. 30.6% (P
ISSN:0390-6078
1592-8721